United Therapeutics Corporation (UTHR)
Automate Your Wheel Strategy on UTHR
With Tiblio's Option Bot, you can configure your own wheel strategy including UTHR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol UTHR
- Rev/Share 66.6837
- Book/Share 151.608
- PB 2.1031
- Debt/Equity 0.0294
- CurrentRatio 5.4606
- ROIC 0.1504
- MktCap 14382239410.0
- FreeCF/Share 25.1359
- PFCF 12.7434
- PE 11.8249
- Debt/Assets 0.0258
- DivYield 0
- ROE 0.1933
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | UTHR | Wells Fargo | Overweight | Equal Weight | -- | -- | April 25, 2025 |
| Upgrade | UTHR | BofA Securities | Underperform | Neutral | -- | $314 | April 21, 2025 |
News
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Read More
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.
Read More
United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Executive Vice President, Product Development and Xenotransplantation James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Joseph Thome - TD Cowen Jessica Fye - JPMorgan Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Roger Song - Jefferies Ash Verma - UBS Operator Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 …
Read More
United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) came out with quarterly earnings of $6.63 per share, beating the Zacks Consensus Estimate of $6.29 per share. This compares to earnings of $6.17 per share a year ago.
Read More
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. “2025 is off to a tremendous start as we reported yet another quarter of record revenue,” said Martine Rothblatt, Ph.D., Chair.
Read More
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations Dewey Steadman - Head, IR Conference Call Participants Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Operator Good morning, and welcome to the United …
Read More
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates.
Read More
United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago.
Read More
United Therapeutics: A Unique Business With High Margins And Expansion Potential
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion.
Read More
About United Therapeutics Corporation (UTHR)
- IPO Date 1999-06-17
- Website https://www.unither.com
- Industry Biotechnology
- CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
- Employees 1305